http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2486526-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a236ebac36d147b0ac204c84a4c614ff |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-533 |
| filingDate | 2012-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76c6a12a291ca57e0fe22b612e4372cf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad94e2f7f5a4400b15ad3fdbec348a9f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a31df43b9e4ea4983cd6c48146c82ca9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0dfee1f777fc950626ef61bbfbf9ee20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39bd50b03f92530565ea7ecd16ce9d2e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d111470e5dc1dadb4bdfc462c8c1b171 |
| publicationDate | 2013-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2486526-C1 |
| titleOfInvention | Method for prediction of clinical effectiveness of interferon therapy of chronic hepatitis c in children |
| abstract | FIELD: medicine. n SUBSTANCE: determining an initial level of total lymphocyte count ≥2500/mcl and CD16+56+ lymphocyte ≥440/mcl count is considered a positive prognostic factor of a virologic reponse to the interferon therapy. An initial level of total lymphocyte count ≤2000/mcl and CD 16+56+ lymphocyte count ≤440/mcl is considered a negative prognostic factor of a virologic reponse. The initial level of total lymphocyte count within the range of 2000-2500 is considered an indication of a follow-up care with underlying treatment. Then, 12 weeks after the interferon therapy, total lymphocyte count, CD3+ lymphocyte count, CD3+CD4+ lymphocyte count and CD16+56+ lymphocyte count in 1 mcl are determined. If observing an increase in total lymphocyte count ≥2500/mcl, CD3+ lymphocyte count ≥1900/mcl, CD3+CD4+lymphocyte count ≥1000/mcl and CD16+56+ lymphocyte count >440/mcl in relation to the initial level, a positive prognosis of the clinical effectiveness of the interferon therapy is concluded. n EFFECT: using the given method enables predicting the clinical effectiveness of the interferon therapy before the beginning thereof and ensuring an individual approach to prescribing the therapy in chronic hepatitis C. n 2 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2646510-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2564933-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2578030-C2 |
| priorityDate | 2012-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 26.